{"id":16988,"date":"2019-03-06T14:21:02","date_gmt":"2019-03-06T13:21:02","guid":{"rendered":"http:\/\/mabdesign.fr\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/"},"modified":"2023-10-17T10:48:16","modified_gmt":"2023-10-17T08:48:16","slug":"ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/","title":{"rendered":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063"},"content":{"rendered":"

\"\"<\/p>\n

OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRP\u03b1 antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors<\/strong><\/p>\n

OSE Immunotherapeutics (ISIN: FR0012127173; Mn\u00e9mo: OSE), today announced authorization by the French National Agency for Medicines and Health Products Safety (ANSM) and by the Belgian Federal Agency for Medicines and Health Products (FAMHP) to initiate a Phase 1 clinical trial for checkpoint inhibitor BI 765063*, a selective SIRP\u03b1 antagonist monoclonal antibody, exclusively licensed to and being developed in collaboration with Boehringer Ingelheim.
\nThe clinical Phase 1 is a dose finding study of monoclonal antibody SIRP\u03b1 antagonist BI 765063*, a myeloid checkpoint inhibitor administered as a single agent and in combination with Boehringer Ingelheim\u2019s monoclonal antibody PD-1 antagonist BI 754091, a lymphocyte T checkpoint inhibitor. The study is conducted by OSE as part of a collaboration and license agreement with Boehringer Ingelheim under which Boehringer Ingelheim obtained exclusive rights to BI 765063. This trial aims to characterize safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in patients with advanced solid tumours.<\/p>\n

To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRP\u03b1 antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors<\/p>\n","protected":false},"author":1,"featured_media":8931,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-16988","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members"],"yoast_head":"\nOSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063 - MabDesign<\/title>\n<meta name=\"description\" content=\"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRP\u03b1 antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063 - MabDesign\" \/>\n<meta property=\"og:description\" content=\"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRP\u03b1 antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-06T13:21:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-17T08:48:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png\" \/>\n\t<meta property=\"og:image:width\" content=\"180\" \/>\n\t<meta property=\"og:image:height\" content=\"60\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063\",\"datePublished\":\"2019-03-06T13:21:02+00:00\",\"dateModified\":\"2023-10-17T08:48:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/\"},\"wordCount\":198,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/\",\"name\":\"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063 - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png\",\"datePublished\":\"2019-03-06T13:21:02+00:00\",\"dateModified\":\"2023-10-17T08:48:16+00:00\",\"description\":\"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRP\u03b1 antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png\",\"width\":180,\"height\":60},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063 - MabDesign","description":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRP\u03b1 antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/","og_locale":"en_US","og_type":"article","og_title":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063 - MabDesign","og_description":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRP\u03b1 antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors","og_url":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/","og_site_name":"MabDesign","article_published_time":"2019-03-06T13:21:02+00:00","article_modified_time":"2023-10-17T08:48:16+00:00","og_image":[{"width":180,"height":60,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png","type":"image\/png"}],"author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063","datePublished":"2019-03-06T13:21:02+00:00","dateModified":"2023-10-17T08:48:16+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/"},"wordCount":198,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/","url":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/","name":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063 - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png","datePublished":"2019-03-06T13:21:02+00:00","dateModified":"2023-10-17T08:48:16+00:00","description":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRP\u03b1 antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/OSE-72dpi.png","width":180,"height":60},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/ose-immunotherapeutics-announces-clinical-trial-authorization-for-a-phase-1-to-evaluate-selective-sirp%ce%b1-antagonist-bi-765063\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 to Evaluate Selective SIRP\u03b1 antagonist BI 765063"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=16988"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16988\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/8931"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=16988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=16988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=16988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}